| Name | Title | Contact Details |
|---|
At Target RWE, we are redefining and revolutionizing the generation and delivery of real-world evidence. Contact us today!
The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.
Renovacor is a preclinical gene therapy company developing a pipeline of innovative and proprietary AAV based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Renovacor`s therapeutic focus is initially on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
Tarcine is a Thousand Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cardiopulmonary Corporation is a Milford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.